Lay summary
Chimeric antigen receptor (CAR) T cell therapy involves treatment of cancer with genetically-engineered immune cells. However, successful CAR T cell therapy of solid cancers is limited by migration and activation of CAR T cells at the tumour site. We will use a dual-safety system to improve CAR T cell function and to localise T cell cytokines directly to the tumour site to enhance cell migration and activation. These original approaches will greatly improve the utility of CAR T cells for the treatment of solid cancers.